Eli Lilly and Company

LLY · NYSE · USD

Can Lilly keep growing revenue at a high rate when price concessions, a slow-building oral launch and payer access limits work against the volume growth of its incretin medicines?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Incretin demand exceeds supply

    The bull case is that demand for incretin medicines outruns supply, so growth is set by manufacturing capacity and access rather than by finding customers.

  • Several incretin formats

    Lilly sells injectable, oral and higher-efficacy incretin medicines, which lets it reach patients who want convenience, deeper weight loss, or a different mechanism.

  • Guidance raised repeatedly

    Management has raised its revenue, margin and earnings targets several times in a year, the clearest sign that spending on plants and trials is turning into sales.

  • Non-incretin franchises growing

    Immunology, oncology and neuroscience medicines are growing faster than the company overall, which reduces the dependence of the whole business on one drug class.

Bear case

  • Price concessions to payers

    The bear case is that every expansion of access comes with a lower price, so the company has to sell steadily more medicine just to keep revenue per prescription flat.

  • Oral launch from low base

    The obesity pill is an unfamiliar brand sold largely through primary care, so its launch must build physician habits and consumer awareness from a low base.

  • Crowded obesity competition

    Competitors are launching their own oral obesity medicines, and Lilly's share leadership means further gains must come from expanding the market rather than taking share.

  • Heavy committed spending

    Cash flow is being committed to new factories and acquisitions, so a slowdown in incretin sales would leave the company carrying spending it has already promised.

Bull and bear points

Growth & Execution

In short: Incretin volume is growing fast, while price cuts and a slow-building oral launch hold back reported revenue.

Bull · 2

  • Cardiometabolic sales nearly doubled from a year earlier

    Incretin medicines now supply most of Lilly's revenue growth, so their prescribing trends decide whether the company meets the revenue targets it has raised three times this year.

    Filed financials

  • Retatrutide moved from cautious data talk to a filing

    A year ago management warned against over-reading the first retatrutide trial; it now says the obesity, sleep apnea and knee arthritis package is complete for a U.S. submission in the first quarter of 2027.

    Tone shiftQ3 FY2025 → Q2 FY2026
Bear · 1

  • Management now guides price to subtract from growth

    A year ago management said pricing was tracking its plan and was not eroding materially; it now guides price to reduce full-year revenue growth by a low-to-mid-teens percentage in 2026.

    Tone shiftQ3 FY2025 → Q4 FY2025

Profitability & Financial Strength

In short: Margins and cash flow are strong, while factory and acquisition spending absorbs a growing share of the cash.

Bull · 2

  • Margin guidance has been raised twice since February

    Management now guides to a performance margin of 49% to 50.5%, up from its February range of 46% to 47.5%, and reported a 54.2% operating margin in the latest quarter.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Free cash flow quadrupled as revenue scaled

    Free cash flow of $18.2 billion over the last twelve months, equal to about 23% of revenue, covers the manufacturing build-out and the buyback from money the business generates.

    Filed financials
Bear · 2

  • Net debt rose while the factory build-out continues

    Net debt climbed to $45.9 billion from $36.4 billion a year earlier, so part of the construction and acquisition program is being funded with borrowing rather than with cash from sales.

    Filed financials

  • Acquisition spending adds charges outside adjusted earnings

    Lilly has bought several clinical-stage companies whose upfront payments are excluded from adjusted earnings, so reported profit growth looks better than the cash actually spent on those deals.

    Q2 FY2026 call

Market Position

In short: Lilly leads the incretin market, while payer coverage terms and a disputed filing pathway limit gains.

Bull · 1

  • Manufacturing scale supports both pills and injections

    Lilly has committed over $55 billion to manufacturing since 2020, and because the oral pill is a small molecule it can be produced in large volumes, which lets the company supply many countries at once.

    Q4 FY2025 call
Bear · 2

  • Medicare obesity coverage runs through a temporary program

    Coverage for seniors comes through a Bridge program that runs only through 2027, after Part D plans declined to opt in, so the largest newly insured group of patients has an end date.

    Q1 FY2026 call

  • Retatrutide's filing pathway is being decided in court

    Lilly wants retatrutide reviewed as a biologic rather than a small molecule and the first court ruling was split, so the timing of a submission management puts in the first quarter of 2027 is not fully in its control.

    Q2 FY2026 call